Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104910 · ClinicalTrials.gov registry record · Phase 1
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
A Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 15
- Study locations
NCT00104910: Completed Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, sponsored by Gynecologic Oncology Group.
NCT00104910 is a Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 64 participants, below the 118-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (46% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104910, a Phase 1 study of Cervical Squamous Cell Carcinoma and Cervical Adenocarcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 15
- Study locations
Study Summary
This phase I trial is studying the side effects and best dose of cetuximab when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Internal radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving cetuximab together with cisplatin and radiation therapy may kill more tumor cells.
Primary Outcome
Evaluation of the regimens will be conducted separately by the type of radiation received (extended field radiation or whole pelvis radiation).
Conditions Studied
Interventions
- DRUG Cisplatin
- BIOLOGICAL Cetuximab
- RADIATION 3-Dimensional Conformal Radiation Therapy
- RADIATION Internal Radiation Therapy
Study Locations (15)
Ohio
- MetroHealth Medical Center - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Riverside Methodist Hospital - Columbus
- Lake University Ireland Cancer Center - Mentor
Texas
- Parkland Memorial Hospital - Dallas
- University of Texas Southwestern Medical Center - Dallas
- M D Anderson Cancer Center - Houston
Georgia
- Georgia Regents University Medical Center - Augusta
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center - Baltimore
New Jersey
- Cooper Hospital University Medical Center - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2005-01 |
| Phase | Phase 1 |
What the finished NCT00104910 record still lists
NCT00104910 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 118-participant average among 13 other Cervical Squamous Cell Carcinoma trials with a reported enrollment target (46% lower).
The record links to 9 conditions, with Cervical Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Cisplatin is the first listed.
NCT00104910 lists 15 locations in 10 states (Ohio, Texas, Georgia).
Frequently Asked Questions
What is clinical trial NCT00104910 about?
NCT00104910 is a clinical study titled "Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer". This phase I trial is studying the side effects and best dose of cetuximab when given together with cisplatin and radiation therapy in treating patients with stage IB, stage II, stage III, or stage IVA cervical cancer. Monoclonal antibodies, such as cetuximab, can block tumor growth in different way...
What is the current status of trial NCT00104910?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2005-01.
What conditions does trial NCT00104910 study?
This clinical trial studies the following conditions: Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Stage IVA Cervical Cancer.
What interventions are being tested in trial NCT00104910?
The interventions under investigation include: Cisplatin (DRUG), Cetuximab (BIOLOGICAL), 3-Dimensional Conformal Radiation Therapy (RADIATION), Internal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT00104910?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104910 being conducted?
This trial has 15 study locations across Georgia, Illinois, Indiana, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00104910's enrollment target sits among peer trials
64 7th of 13 higher than 7 of 13 other Cervical Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
RECRUITING · Phase 1
-
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
RECRUITING · Phase 1
-
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia